orasur technolog inc specimen
collect vitro diagnost compani
primarili engag develop
manufactur market sale collect
devic proprietari oral fluid technolog
requir disclosur end report
even lumpi pt
orasur technolog particip annual cl king best
idea confer thursday septemb new york citi see
list
confirm
click
oper strong quarter beat
top bottom line guid revenu consensu estim
said revenu line help lot investor probabl
hope compani miss dna genotek lastli investor hope
divestitur busi except dna genotek like littl
disappoint stock like remain optimist
long-term opportun dna genotek thesi osur exposur
blossom consum genom market give signific strateg valu overal
think massiv upsid consum genom number revenu
especi margin perspect even face dna genotek miss
reiter buy thesi decreas price target
crux argument anoth dna genotek miss investor
come grip lap comp strong consum genom
backdrop expect stock somewhat today ultim
question becom five-year compound-annual-growth-rate consum genom
anticip orasur supplier kit provid maintain view
growth driven ilmna dedic
market given orasur competit moat increas suppli contract
expect grow tandem market
number orasur post revenu vs last year
estim street beat driven hiv
intern barda ancestri com royalti payment rel
model ep vs our/th street estim although fair
compani higher royalti payment rel model also
duplic manag cost
guidanc orasur guid revenu
street even rais expect
compani guidanc beatabl
product revenu miss net product revenu year
year miss estim miss attribut two
factor tough comp molecular collect end hcv
revenu countrywid elimin deal
molecular collect molecular collect vs
last year said sequenti commerci segment
includ consum genom year year sequenti
orasur ancestri com royalti payment
partnership ancestri com revenu suggest robust growth market
continu inde mere lumpi
strateg review surpris one orasur decid like
dna genotek busi build around also continu de-
emphas potenti divest risk assess cryosurg mostli
specul divestitur thing margin
controversi strateg review possibl compani would
will sell infecti diseas ultim look like orasur keep
infecti diseas even potenti invest think compani could
add third leg direct-to-consum dtc diagnost product saliva test
product life scienc tool overal think strateg review creat
overhang stock final clear
hiv upsid driver hiv revenu
last year orasur note major revenu independ
psi popul servic project suggest
project end orasur hiv self-test could continu
key contributor growth compani increas product even though
infecti diseas drag right anticip higher volum contribut
oper incom recal gate foundat deal could repres
revenu next four year fund deploy hand
countri sub-saharan africa help protect margin near term
model rais respect revenu estim
also increas
adjust ep estim
respect addit introduc respect revenu
ep estim
reiter buy rate new price target base
ev/sal multipl previous revis revenu
project
risk achiev price target
depend contract
demand diseas erad effort
rapport lead health organ govern agenc
view current cl king meet event calendar coverag univers
page
